Evidence map›Paper›PMID 16148285›Full record

ArticleThe New England journal of medicine2005

Circulating endothelial progenitor cells and cardiovascular outcomes.

Nikos Werner, Sonja Kosiol, Tobias Schiegl, Patrick Ahlers, Katrin Walenta, Andreas Link, Michael Böhm, Georg Nickenig

4 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in The New England journal of medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 689 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
689citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02964585 phase4completedstarted 2016, after this paper: background citation

Role of Canagliflozin on Gene Expression and Function of CD34+ Endothelial Progenitor Cells and Renal Function in Patients With Type 2 Diabetes

Ran2016Enrolled34Registered outcomes18Posted comparisons0ConditionsType 2 Diabetes MellitusArmsCanagliflozin, Placebo
PMID 26378978PMID 24631482PMID 24357209PMID 24334174PMID 16028691PMID 33581737PMID 23362314PMID 19339628PMID 17562958PMID 17179929other papers from this trial
Open the trial in the graph
NCT00699686 phase4completednot on this mapstarted 2008, after this paper: background citation

Effects of Optimized Glycemic Control Achieved With add-on Basal Insulin Therapy on Indexes of Endothelial Damage and Regeneration in Type 2 Diabetic Patients With Macroangiopathy. A Randomized Cross-over Trial Comparing Detemir vs Glargine

TypeinterventionalSponsorUniversity of PadovaRan2008 to 2010Enrolled50ConditionsType 2 Diabetes, Endothelial Dysfunction, Cardiovascular DiseaseArmsGlargine, Detemir
NCT00729859 phase2completednot on this mapstarted 2008, after this paper: background citation

Hormonal Regulation of Circulating Endothelial Progenitor Cells and HDL-C in Men Title Changed With New Protocol (12/14/09): Hormonal Regulation of HDL-C in Men

TypeinterventionalSponsorUniversity of WashingtonRan2008 to 2010Enrolled31ConditionsHealthyArmsAcyline, Acyline + Testosterone gel, Acyline + testosterone gel + anastrozole
NCT02694575 completednot on this mapstarted 2015, after this paper: background citation

The Impact of Glucose Lowering Therapies Including Dipeptidyl Peptidase-4 Inhibitor on Circulating Endothelial Progenitor Cells (EPCs) and Its Mobilising Factor Stromal Derived Factor-1α (SDF-1α) in Patients With Type 2 Diabetes

TypeobservationalSponsorUniversity of LeicesterRan2015 to 2018Enrolled241ConditionsDiabetes Mellitus, Type 2, Cardiovascular Diseases
3 · Its place in the literature

Who cites it

689 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. CD34Histology and histopathology · 2026
    Review
  19. Article
  20. Review

629 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Nikos WernerDivision of Cardiology, Angiology, and Intensive Care Medicine, Department of Internal Medicine, University of Saarland, Homburg-Saar, Germany.
Sonja Kosiol
Tobias Schiegl
Patrick Ahlers
Katrin Walenta
Andreas Link
Michael Böhm
Georg Nickenig

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEndothelial progenitor cells derived from bone marrow are believed to support the integrity of the vascular endothelium. The number and function of endothelial progenitor cells correlate inversely with cardiovascular risk factors, but the prognostic value associated with circulating endothelial progenitor cells has not been defined.

methodsThe number of endothelial progenitor cells positive for CD34 and kinase insert domain receptor (KDR) was determined with the use of flow cytometry in 519 patients with coronary artery disease as confirmed on angiography. After 12 months, we evaluated the association between baseline levels of endothelial progenitor cells and death from cardiovascular causes, the occurrence of a first major cardiovascular event (myocardial infarction, hospitalization, revascularization, or death from cardiovascular causes), revascularization, hospitalization, and death from all causes.

resultsA total of 43 participants died, 23 from cardiovascular causes. A first major cardiovascular event occurred in 214 patients. The cumulative event-free survival rate increased stepwise across three increasing baseline levels of endothelial progenitor cells in an analysis of death from cardiovascular causes, a first major cardiovascular event, revascularization, and hospitalization. After adjustment for age, sex, vascular risk factors, and other relevant variables, increased levels of endothelial progenitor cells were associated with a reduced risk of death from cardiovascular causes (hazard ratio, 0.31; 95 percent confidence interval, 0.16 to 0.63; P=0.001), a first major cardiovascular event (hazard ratio, 0.74; 95 percent confidence interval, 0.62 to 0.89; P=0.002), revascularization (hazard ratio, 0.77; 95 percent confidence interval, 0.62 to 0.95; P=0.02), and hospitalization (hazard ratio, 0.76; 95 percent confidence interval, 0.63 to 0.94; P=0.01). Endothelial progenitor-cell levels were not predictive of myocardial infarction or of death from all causes.

conclusionsThe level of circulating CD34+KDR+ endothelial progenitor cells predicts the occurrence of cardiovascular events and death from cardiovascular causes and may help to identify patients at increased cardiovascular risk.

Indexed as

Endothelial CellsStem CellsAgedAged, 80 and overAnalysis of VarianceAntigens, CD34BiomarkersCardiovascular DiseasesCell CountColony-Forming Units AssayCoronary DiseaseDisease-Free SurvivalFemaleFollow-Up StudiesHumansIncidenceAntigens, CD34BiomarkersVascular Endothelial Growth Factor Receptor-2

Identifiers

PMID16148285

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.